Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

NCT00323063 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

49

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Breast Cancer

Interventions

DRUG: gemcitabine hydrochloride
DRUG: imatinib mesylate

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]
[object Object]
[object Object]